Skip to main content
S&P 5007,521.00-0.94%DOW52,170.76-0.24%NASDAQ24,962.90-1.59%BTC$68,657.00-4.21%ETH$1,929.72-3.62%GOLD$3,885.300.00%OIL$88.53-0.24%
Smart Investors Daily
SID Premium
GH

NASDAQ · GH

Guardant Health, Inc.

Healthcare · Medical - Diagnostics & Research

$154.86

Down-$3.97 (-2.56%)

Updated Nov 13, 2026, 3:46 PM

SID Score

6.2/10

Composite research score

Smart Money

59/100

Neutral

Market cap
12.58B
P/E ratio
-31.72
Dividend yield
0.00%
52-week range
$74.55 – $191.05
Volume
3.5M
Avg. volume
2.66M

Price performance · GH

GH price history

1M range · 0 trading sessions · Daily adjusted prices

GH does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest GH news

The latest Smart Investors Daily articles mentioning GH.

Stock researchCompany · Overview

GH research

Overview

Company profile and research snapshot.

Company profile

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$93.00
Implied upside
—
Analysts
—
GH recent ratings
DateFirmRatingTarget
Nov 10, 2026Piper SandlerOverweight—
Oct 27, 2026BTIGBuy—
Oct 23, 2026Roth CapitalBuy—
Oct 13, 2026Morgan StanleyOverweight—
Oct 7, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 7, 2026

Guardant Health (GH) Now Has A Harder Patent Fight After 23 Claims Survived

Guardant Health (NasdaqGS:GH) faces higher legal pressure after the USPTO confirmed patentability of TwinStrand's Duplex Sequencing patent claims. The US patent office upheld all 23 claims in TwinStrand Biosciences' core Duplex Sequencing patent in a now unappealable ruling. This confirmation supports TwinStrand's ongoing lawsuit that accuses Guardant Health of willful infringement related to its cancer testing technology. The USPTO decision on TwinStrand's Duplex Sequencing patent should...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By